mitomycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antineoplastics, nucleotoxic agents	1819	50-07-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: mitomycin mutamycin Mitomycin C	An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis. Molecular weight: 334.33 Formula: C15H18N4O5 CLOGP: -0.80 LIPINSKI: 0 HAC: 9 HDO: 3 TPSA: 146.89 ALOGS: -1.52 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

mitomycin
mutamycin
Mitomycin C

An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.

Molecular weight: 334.33
Formula: C15H18N4O5
CLOGP: -0.80
LIPINSKI: 0
HAC: 9
HDO: 3
TPSA: 146.89
ALOGS: -1.52
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
S (Water solubility)	0.50 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Bocci G, Oprea TI, Benet LZ
fu (Fraction unbound in plasma)	0.79 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

Date	Agency	Company	Orphan
Aug. 24, 1981	FDA
Dec. 23, 2022	PMDA	Kyowa Kirin Co., Ltd.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Off label use	108.08	29.19	122	2018	674340	62812542
Pulmonary veno-occlusive disease	105.56	29.19	20	2120	1101	63485781
Conjunctival filtering bleb leak	97.52	29.19	11	2129	6	63486876
Haemolytic uraemic syndrome	84.09	29.19	19	2121	2484	63484398
Iris transillumination defect	69.59	29.19	10	2130	94	63486788
Scleral thinning	66.68	29.19	8	2132	13	63486869
Leukopenia	58.78	29.19	35	2105	77255	63409627
Scleromalacia	58.11	29.19	7	2133	12	63486870
Mucosal inflammation	57.11	29.19	29	2111	46899	63439983
Malignant neoplasm progression	56.82	29.19	35	2105	82086	63404796
Neutropenia	54.76	29.19	46	2094	174959	63311923
Thrombocytopenia	52.01	29.19	42	2098	151115	63335767
Bladder perforation	50.05	29.19	8	2132	160	63486722
Radiation skin injury	47.57	29.19	10	2130	933	63485949
Eye infection toxoplasmal	45.55	29.19	8	2132	287	63486595
Hypotony of eye	43.37	29.19	7	2133	149	63486733
Necrotising scleritis	43.33	29.19	7	2133	150	63486732
Tractional retinal detachment	42.73	29.19	6	2134	47	63486835
Pancytopenia	39.95	29.19	30	2110	96903	63389979
Extravasation	38.39	29.19	10	2130	2362	63484520
Rhegmatogenous retinal detachment	38.03	29.19	6	2134	110	63486772
Acute promyelocytic leukaemia	36.41	29.19	8	2132	919	63485963
Disease progression	31.75	29.19	29	2111	122729	63364153
Encapsulating peritoneal sclerosis	31.41	29.19	6	2134	344	63486538
Conjunctival erosion	30.45	29.19	5	2135	119	63486763
Metastases to liver	29.87	29.19	15	2125	23624	63463258
Thrombotic thrombocytopenic purpura	29.33	29.19	9	2131	3827	63483055

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Off label use	108.57	31.48	123	1800	419401	34535607
Conjunctival filtering bleb leak	83.41	31.48	10	1913	6	34955002
Bladder perforation	80.20	31.48	14	1909	292	34954716
Iris hypopigmentation	64.04	31.48	9	1914	40	34954968
Scleral thinning	57.34	31.48	7	1916	6	34955002
NPM1 gene mutation	55.55	31.48	9	1914	117	34954891
Bronchiolitis obliterans syndrome	51.13	31.48	9	1914	197	34954811
Chimerism	49.64	31.48	9	1914	234	34954774
Post embolisation syndrome	45.26	31.48	7	1916	66	34954942
Bladder necrosis	44.05	31.48	5	1918	0	34955008
Scrotal ulcer	37.70	31.48	8	1915	475	34954533
Gastric perforation	37.28	31.48	11	1912	2509	34952499
Hypotony of eye	35.30	31.48	6	1917	106	34954902
Eosinophilic cystitis	34.46	31.48	5	1918	29	34954979
Blood immunoglobulin G decreased	33.49	31.48	9	1914	1464	34953544
Dysuria	33.47	31.48	20	1903	27132	34927876

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Conjunctival filtering bleb leak	176.93	27.26	21	4084	12	79740271
Off label use	173.02	27.26	221	3884	906994	78833289
Scleral thinning	151.05	27.26	19	4086	29	79740254
Bladder perforation	126.36	27.26	21	4084	346	79739937
Hypotony of eye	111.87	27.26	18	4087	240	79740043
Scleromalacia	103.66	27.26	14	4091	47	79740236
Pulmonary veno-occlusive disease	100.42	27.26	22	4083	1626	79738657
Iris hypopigmentation	77.44	27.26	11	4094	58	79740225
Mucosal inflammation	74.22	27.26	47	4058	75533	79664750
Iris transillumination defect	68.26	27.26	11	4094	148	79740135
NPM1 gene mutation	62.37	27.26	10	4095	130	79740153
Encapsulating peritoneal sclerosis	61.07	27.26	13	4092	838	79739445
Haemolytic uraemic syndrome	60.83	27.26	18	4087	4431	79735852
Chimerism	54.89	27.26	10	4095	286	79739997
Radiation skin injury	54.32	27.26	13	4092	1421	79738862
Endophthalmitis	54.30	27.26	18	4087	6410	79733873
Neutropenia	53.91	27.26	70	4035	287640	79452643
Bronchiolitis obliterans syndrome	53.54	27.26	10	4095	329	79739954
Conjunctival erosion	52.30	27.26	9	4096	184	79740099
Post embolisation syndrome	51.73	27.26	8	4097	81	79740202
Extravasation	50.51	27.26	15	4090	3735	79736548
Eosinophilic cystitis	50.04	27.26	8	4097	102	79740181
Leukopenia	49.86	27.26	44	4061	116469	79623814
Gastric perforation	49.42	27.26	15	4090	4022	79736261
Thrombocytopenia	47.28	27.26	63	4042	265196	79475087
Bladder necrosis	45.46	27.26	6	4099	16	79740267
Necrotising scleritis	43.61	27.26	8	4097	238	79740045
Pupillary disorder	42.48	27.26	9	4096	567	79739716
Scrotal ulcer	39.15	27.26	8	4097	422	79739861
Blebitis	38.88	27.26	5	4100	10	79740273
Acute promyelocytic leukaemia	38.79	27.26	10	4095	1481	79738802
Visual acuity reduced	38.40	27.26	22	4083	29447	79710836
Eye infection toxoplasmal	37.16	27.26	8	4097	544	79739739
Pancytopenia	36.86	27.26	44	4061	165701	79574582
Conjunctival bleb	36.68	27.26	6	4099	89	79740194
Tractional retinal detachment	36.62	27.26	6	4099	90	79740193
Choroidal detachment	36.03	27.26	8	4097	628	79739655
Palmar-plantar erythrodysaesthesia syndrome	36.01	27.26	22	4083	33112	79707171
Chemical cystitis	35.50	27.26	4	4101	0	79740283
Acute myeloid leukaemia recurrent	34.79	27.26	11	4094	3372	79736911
Second primary malignancy	33.97	27.26	16	4089	14334	79725949
Rhegmatogenous retinal detachment	32.34	27.26	6	4099	190	79740093
Hepatic artery stenosis	32.22	27.26	6	4099	194	79740089
Dysuria	31.81	27.26	24	4081	50927	79689356
Blood immunoglobulin G decreased	30.62	27.26	10	4095	3399	79736884
Steroid diabetes	30.34	27.26	10	4095	3496	79736787
Anterior chamber pigmentation	30.21	27.26	4	4101	11	79740272
Disease progression	30.09	27.26	42	4063	184320	79555963
Corneal oedema	28.95	27.26	9	4096	2611	79737672
Hyphaema	28.15	27.26	7	4098	897	79739386

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01DC03	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES Other cytotoxic antibiotics
FDA MoA	N0000000236	Alkylating Activity
FDA EPC	N0000175558	Alkylating Drug
CHEBI has role	CHEBI:35610	antineoplastic agents
MeSH PA	D000477	Alkylating Agents
MeSH PA	D000903	Antibiotics, Antineoplastic
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D003432	Cross-Linking Reagents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D007202	Indicators and Reagents
MeSH PA	D009676	Noxae
MeSH PA	D019384	Nucleic Acid Synthesis Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Adenocarcinoma of pancreas	indication	700423003	DOID:4074
Metastatic Gastric Cancer	indication
Adjunct to incisional glaucoma surgery	indication
Non-small cell lung cancer	off-label use	254637007	DOID:3908
Malignant tumor of head and/or neck	off-label use	255056009
Malignant tumor of anus	off-label use	363490009	DOID:14110
Malignant tumor of urinary bladder	off-label use	399326009	DOID:11054
Prevention of Recurrent Bladder Carcinoma	off-label use
Corneal Conjunctival Intraepithelial Neoplasm	off-label use
Stomatitis	contraindication	61170000	DOID:9637
Acute infectious disease	contraindication	63171007
Blood coagulation disorder	contraindication	64779008	DOID:1247
Heart failure	contraindication	84114007	DOID:6000
Leukopenia	contraindication	84828003	DOID:615
Kidney disease	contraindication	90708001	DOID:557
Hemolytic uremic syndrome	contraindication	111407006	DOID:12554
Anemia	contraindication	271737000	DOID:2355
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Bone marrow depression	contraindication	307762000
Breastfeeding (mother)	contraindication	413712001
Pulmonary Infiltrates	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.54	acidic
pKa2	10.39	Basic
pKa3	7.53	Basic
pKa4	4.95	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
0.2MG/VIAL	MITOSOL	MOBIUS THERAP	N022572	Feb. 7, 2012	RX	FOR SOLUTION	TOPICAL	9539241	Jan. 2, 2028	MITOSOL IS AN ANTIMETABOLITE INDICATED AS AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY. IT IS INTENDED FOR TOPICAL APPLICATION TO THE SITE OF GLAUCOMA FILTRATION SURGERY
0.2MG/VIAL	MITOSOL	MOBIUS THERAP	N022572	Feb. 7, 2012	RX	FOR SOLUTION	TOPICAL	9649428	May 21, 2029	MITOSOL IS AN ANTIMETABOLITE INDICATED AS AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY. IT IS INTENDED FOR TOPICAL APPLICATION TO THE SITE OF GLAUCOMA FILTRATION SURGERY

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
40MG/VIAL	JELMYTO	UROGEN PHARMA	N211728	April 15, 2020	RX	POWDER	PYELOCALYCEAL	April 15, 2023	NEW PRODUCT
40MG/VIAL	JELMYTO	UROGEN PHARMA	N211728	April 15, 2020	RX	POWDER	PYELOCALYCEAL	April 15, 2027	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CANCER (LG-UTUC)

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Indoleamine 2,3-dioxygenase 1	Enzyme	P14902	I23O1_HUMAN		Ki	4.60		CHEMBL

External reference:

ID	Source
4018134	VUID
N0000146471	NUI
D00208	KEGG_DRUG
4018134	VANDF
C0002475	UMLSCUI
CHEBI:27504	CHEBI
CHEMBL105	ChEMBL_ID
D016685	MESH_DESCRIPTOR_UI
DB00305	DRUGBANK_ID
3043	INN_ID
50SG953SK6	UNII
5746	PUBCHEM_CID
204298	RXNORM
1274	MMSL
140168	MMSL
1973	MMSL
5122	MMSL
d00305	MMSL
002660	NDDF
387331000	SNOMEDCT_US
59240002	SNOMEDCT_US
7089	IUPHAR_LIGAND_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Mitomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9135	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	ANDA	17 sections
Mitomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9136	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	40 mg	INTRAVENOUS	ANDA	17 sections
Mitomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9279	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	ANDA	17 sections
Mitomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9279	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	ANDA	17 sections
Mitomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9280	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	40 mg	INTRAVENOUS	ANDA	17 sections
Mitomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9280	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	40 mg	INTRAVENOUS	ANDA	17 sections
Mitomycin	HUMAN PRESCRIPTION DRUG LABEL	1	16729-108	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	ANDA	18 sections
Mitomycin	HUMAN PRESCRIPTION DRUG LABEL	1	16729-108	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	ANDA	18 sections
Mitomycin	HUMAN PRESCRIPTION DRUG LABEL	1	16729-115	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	5 mg	INTRAVENOUS	ANDA	18 sections
Mitomycin	HUMAN PRESCRIPTION DRUG LABEL	1	16729-115	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	5 mg	INTRAVENOUS	ANDA	18 sections
Mitomycin	HUMAN PRESCRIPTION DRUG LABEL	1	16729-116	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	40 mg	INTRAVENOUS	ANDA	18 sections
Mitomycin	HUMAN PRESCRIPTION DRUG LABEL	1	16729-116	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	40 mg	INTRAVENOUS	ANDA	18 sections
Mitomycin	HUMAN PRESCRIPTION DRUG LABEL	1	16729-246	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	5 mg	INTRAVENOUS	ANDA	18 sections
Mitomycin	HUMAN PRESCRIPTION DRUG LABEL	1	16729-247	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	ANDA	18 sections
Mitomycin	HUMAN PRESCRIPTION DRUG LABEL	1	16729-248	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	40 mg	INTRAVENOUS	ANDA	18 sections
Mitomycin	HUMAN PRESCRIPTION DRUG LABEL	1	25021-250	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	5 mg	INTRAVENOUS	ANDA	19 sections
Mitomycin	HUMAN PRESCRIPTION DRUG LABEL	1	25021-251	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	ANDA	19 sections
Mitomycin	HUMAN PRESCRIPTION DRUG LABEL	1	25021-252	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	40 mg	INTRAVENOUS	ANDA	19 sections
MITOMYCIN	HUMAN PRESCRIPTION DRUG LABEL	1	65219-564	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	5 mg	INTRAVENOUS	ANDA	15 sections
MITOMYCIN	HUMAN PRESCRIPTION DRUG LABEL	1	65219-566	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	ANDA	15 sections
MITOMYCIN	HUMAN PRESCRIPTION DRUG LABEL	1	65219-568	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	40 mg	INTRAVENOUS	ANDA	15 sections
Mitomycin	HUMAN PRESCRIPTION DRUG LABEL	1	67457-518	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	5 mg	INTRAVENOUS	ANDA	16 sections
Mitomycin	HUMAN PRESCRIPTION DRUG LABEL	1	67457-519	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	ANDA	16 sections
Mitomycin	HUMAN PRESCRIPTION DRUG LABEL	1	67457-520	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	40 mg	INTRAVENOUS	ANDA	16 sections
Mitomycin	HUMAN PRESCRIPTION DRUG LABEL	1	67457-995	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	5 mg	INTRAVENOUS	ANDA	16 sections
Mitomycin	HUMAN PRESCRIPTION DRUG LABEL	1	67457-996	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	ANDA	16 sections
Mitomycin	HUMAN PRESCRIPTION DRUG LABEL	1	67457-997	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	40 mg	INTRAVENOUS	ANDA	16 sections
Mitomycin	HUMAN PRESCRIPTION DRUG LABEL	1	68001-389	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	5 mg	INTRAVENOUS	ANDA	18 sections
Mitomycin	HUMAN PRESCRIPTION DRUG LABEL	1	68001-390	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	ANDA	18 sections
Mitomycin	HUMAN PRESCRIPTION DRUG LABEL	1	68001-391	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	40 mg	INTRAVENOUS	ANDA	18 sections